(Total Views: 332)
Posted On: 02/25/2022 7:06:01 AM
Post# of 5
THE UNRAVELLING OF KODIAK SCIENCES
$KOD
Kodiak Sciences, Inc. (NASDAQ: KOD), a clinical-stage biotechnology Company focused on creating novel therapeutics for the treatment of retinal diseases announced disappointing results from a Phase 2b/3 clinical trial evaluating KSI-301, a novel antibody biopolymer conjugate, intended for the treatment of neovascular (wet) age-related macular degeneration.
The stock of the Company has plummeted by 80% in the aftermath of the news.
Read on to find out more!
https://www.aviseanalytics.com/the-unravellin...-sciences/
$KOD
Kodiak Sciences, Inc. (NASDAQ: KOD), a clinical-stage biotechnology Company focused on creating novel therapeutics for the treatment of retinal diseases announced disappointing results from a Phase 2b/3 clinical trial evaluating KSI-301, a novel antibody biopolymer conjugate, intended for the treatment of neovascular (wet) age-related macular degeneration.
The stock of the Company has plummeted by 80% in the aftermath of the news.
Read on to find out more!
https://www.aviseanalytics.com/the-unravellin...-sciences/
(0)
(0)Scroll down for more posts ▼
